AOD9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Technology == Dr. Werner Baumgartner was responsible for founding Psychemedics and spearheading its initial research. A nationally recognized expert on drug testing through hair samples, Dr. Baumgartner gained acclaim by procuring some strands of hair from the 19th-century poet John Keats. Despite the age of the hair, Baumgartner was able to detect that the poet, who died at the age of 26 from tuberculosis, had been taking an increasing amount of opium before his death, most likely used in painkillers. Dr. Baumgartner's find created a minor sensation, enough to warrant a mention in a 1985 Time magazine cover story about drugs in the workplace. After years of research proved that drugs deposited in the hair can be accurately measured, the company was formed in 1987 and pioneered the use of hair testing in commercial markets including banks, manufacturers, retailers, mining operations, hotels and casinos. The technology capitalizes on the way the body metabolizes ingested drugs as they flow through the blood stream and deposit in the cortex of the hair. Hair is stable and the deposits are permanently embedded in the hair, so hair acts like a tape recorder — “recording” drug deposits in proportion to use over time as drugs are deposited in proportion to use. Hair grows at approximately the rate of ½ an inch per month and takes about 5 days to grow out past the external layer of skin. Psychemedics’ standard test uses a 1 ½ inch sample of head hair, which provides an approximate 3 month history of drug use. Body hair can also be collected if head hair is not available.
The receptors for enkephalin are the δ-opioid receptor (DOR) and μ-opioid receptor (MOR). Opioid receptors are a group of G-protein-coupled receptors, with other opioids as ligands as well. The other endogenous opioids are dynorphins (that bind to κ-opioid receptor), endorphins (MOR), endomorphins, and nociceptin-orphanin FQ. The opioid receptors are ~40% identical to somatostatin receptors (SSTRs).
=== ADHD === Selegiline has been limitedly studied in the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. In a small randomized trial of selegiline for treatment of ADHD in children, there were improvements in attention, hyperactivity, and learning/memory performance but not in impulsivity. A small clinical randomized trial compared selegiline to methylphenidate, a first line treatment for ADHD, and reported equivalent efficacy as assessed by parent and teacher ratings. In another small randomized controlled trial of selegiline for the treatment of adult ADHD, a high dose of the medication for 6 weeks was not significantly more effective than placebo in improving symptoms. Selegiline in its transdermal patch form (brand name Emsam) has also been assessed in the treatment of ADHD in children and adolescents in a small open-label pilot study sponsored by the manufacturer in 2003. However, there was a high rate of discontinuation and development was not further pursued.
=== June === 2 June – China successfully lands Chang'e 6 on the lunar far side. The robotic probe is set to begin sample collection before returning its 2 kg (4.4 lb) cargo on 4 June. 4 June – The China National Space Administration's Chang'e 6 spacecraft lifts off from the surface of the far side of the Moon carrying samples of lunar soil and rocks back to Earth. 5 June – Astronomers identify ASKAP J1935+2148, the slowest-spinning neutron star ever recorded, which completes a rotation just once every 54 minutes. 8 June – A paper challenges the public perception and media depictions of large language models like especially ChatGPT, arguing that "bullshitting" in the sense of the book On Bullshit and a fundamentally flawed design are a better approach or terminology for understanding the flaws of these AI architectures or the behavior of the systems based on these as opposed to occasional or frequent "hallucinations". In agreement with many other experts, they find these models are in an "important way indifferent to the truth of their outputs". This notion has also been applied to Perplexity AI that is typically used for generating outputs that are less inaccurate than ChatGPT's – or contain fewer "hallucinations" – and which was scaled up substantially during 2024. An investigation by WIRED reportedly showed the chatbot at times closely paraphrased WIRED stories, and at times summarized stories inaccurately and with minimal attribution.
Sources: en.wikipedia.org
The first strategy, referred to as "prolonged resistance" on state television, would involve several small military units carrying out sabotage and other guerrilla-style tactics, according to sources. The second strategy that was not officially mentioned, "anarchization", aims to "make Venezuela ungovernable for foreign forces" by creating disorder in the capital, Caracas. The approach, labeled an acknowledgement of Venezuela's "debilitated" military, would be unlikely to succeed, as noted by sources. After USS Gravely arrived in Trinidad and Tobago on 26 October, Venezuela condemned that country's joint drills with the US, referring to them as a "military provocation", and withdrew from an energy agreement it had established with the island nation in 2015. Vice President Delcy Rodríguez claimed without evidence that Venezuela had captured a group of mercenaries "with direct information of the American intelligence agency" whose goal was to carry out a false flag attack in the region. Minister of the Interior Diosdado Cabello said on 27 October the captured cell was four members "financed by the CIA" who had plans to blame Venezuela for an attack on the Gravely.
=== Reference materials === Reference materials are compounds which are carefully calibrated against the primary reference or a calibration material. These compounds allow for isotopic analysis of materials differing in chemical or isotopic composition from the compounds defining the isotopic scales on which measurements are reported. In general these are the materials most researchers mean when they say "reference materials". An example of a reference material is USGS-34, a KNO3 salt with a δ15N of -1.8‰ vs. AIR. In this case the reference material has a mutually agreed upon value of δ15N when measured relative to the primary reference of atmospheric N2 (Böhlke et al., 2003). USGS-34 is useful because it allows researchers to directly measure the 15N/14N of NO3− in natural samples against the standard and report observations relative to N2 without having to first convert the sample to N2 gas.
== Isolation and synthesis == Vinblastine may be isolated from the Madagascar Periwinkle (Catharanthus roseus), its only known biological producer, along with several of its precursors, catharanthine and vindoline. Extraction is costly and yields of vinblastine and its precursors are low, although procedures for rapid isolation with improved yields avoiding auto-oxidation have been developed. Enantioselective synthesis has been of considerable interest in recent years, as the natural mixture of isomers is not an economical source for the required C16'S, C14'R stereochemistry of biologically active vinblastine. Initially, the approach depends upon an enantioselective Sharpless epoxidation, which sets the stereochemistry at C20. The desired configuration around C16 and C14 can then be fixed during the ensuing steps. In this pathway, vinblastine is constructed by a series of cyclization and coupling reactions which create the required stereochemistry. The overall yield may be as great as 22%, which makes this synthetic approach more attractive than extraction from natural sources, whose overall yield is about 10%. Stereochemistry is controlled through a mixture of chiral agents (Sharpless catalysts), and reaction conditions (temperature, and selected enantiopure starting materials). Due to difficulty of stereochemical restraints in total synthetic processes, other semi-synthetic methods from precursors, catharanthine and vindoline, continue to be developed.
Sources: en.wikipedia.org
==== Computer tomography ==== In 1972, the first commercial CT scanner for clinical use went into operation at Atkinsons Morley Hospital in London. Its inventor was the English engineer Godfrey Newbold Hounsfield (1919-2004), who shared the 1979 Nobel Prize in Medicine with Allan McLeod Cormack (1924-1998) for his pioneering work in the field of computed tomography. The first steps toward dose reduction were taken in 1989 in the era of single-slice spiral CT. The introduction of multi-slice spiral computed tomography in 1998 and its continuous development made it possible to reduce the dose by means of dose modulation. The tube current is adjusted, for example by reducing the power for images of the lungs compared to the abdomen. The tube current is modulated during rotation. Because the human body has an approximately oval cross-section, radiation intensity is reduced when radiation is delivered from the front or back, and is increased when radiation is delivered from the side. This dose control also depends on the body mass index. For example, the use of dose modulation in the head and neck region reduces total exposure and organ doses to the thyroid and eye lens by up to 50% without significantly compromising diagnostic image quality. The Computed Tomography Dose Index (CTDI) is used to measure radiation exposure during a CT scan. The CTDI was first defined by the Food and Drug Administration (FDA) in 1981. The unit of measurement for the CTDI is the mGy (milli-Gray).
The closest relatives within the genus are Ambrosiella xylebori, the symbiont of Xylosandrus compactus (the black twig borer), and Ambrosiella grosmanniae, the symbiont of Xylosandrus germanus (the black stem borer). The genera of Ceratocystidaceae have been revised multiple times based on molecular data, incorporating sequences derived from other Ambrosiella species but not necessarily A. roeperi (and sometimes only including Ambrosiella that have now been moved elsewhere). These analyses imply the genus is most closely related to Huntiella. Within this taxon, studies incorporating the LSU rDNA of A. roeperi suggest that it, A. xylebori, A. hartigii, and A. beaveri comprise a monophyletic lineage excluding A. ferruginea (now Phialoporopsis ferruginea) and most closely aligned to Ceratocystis adiposa, subsequent analysis using 18S rDNA and translation elongation factor alpha confirms this and suggests a monophyletic clade of Ambrosiella associated with the scolytine tribe Xyleborini.
Calcium acetate - their coordination complexes Poly(alkyl methacrylate) - especially poly(isobutyl methacrylate) Polystyrene Aluminum oxide - (some grades) Paraffin wax Aluminum alcoholate (ISO-series) Silicon dioxide (some grades) Natural rubber (LA-series) tetraoxyborate - their coordination complexes Casein Sulfur (polysulfides) Polybutadiene Asphalt - and other organic minerals Bentonite clay (lyophilic type) Colloidal metal Metallic soaps - especially hydroxyaluminum soaps Cellulose derivatives Metal alkyls - especially dialkyl hydroxygallium and trialkyltin fluorides Carbomer Alginate
Potentiation of GABAA receptor activity (by kavain, dihydrokavain, methysticin, dihydromethysticin, and yangonin). Inhibition of the reuptake of norepinephrine (by kavain and methysticin) and possibly also of dopamine (by kavain and desmethoxyyangonin). Binding to the CB1 receptor (by yangonin). Inhibition of voltage-gated sodium channels and voltage-gated calcium channels (by kavain and methysticin). Monoamine oxidase B reversible inhibition (by all six of the major kavalactones). Methanolic leaf extracts of Hawaiian kava cultivars showed stronger binding inhibition to several CNS receptors—including GABAA, dopamine D2, opioid (μ, δ), and histamine (H1, H2)—than root extracts, suggesting that compounds beyond the main kavalactones may contribute to the pharmacological effects of kava leaves.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.